Clinical Research Directory

Inclusion Criteria: * Male or female ≥ 18 and ≤75 years of age. * Eastern Cooperative Oncology Group Performance Status score of 0 or 1. * Participants with histologically or cytologically confirmed advanced solid tumors. * At least one measurable lesion according to RECIST v1.1. * Expected survival time ≥ 3 months as judged by the Investigator. Exclusion Criteria: * Participants have received prior therapy with antibody-drug conjugates bearing a camptothecin or camptothecin derivative payload. * Participants who have received any chemotherapy, any anti-tumor therapy (including monoclonal antibodies, targeted therapy, radioimmunoconjugates, or Antibody-Drug Conjugates), or other investigational drugs within 28 days or 5 half-lives (whichever is shorter) prior to the first dose of investigational product. * Participants who have received major surgery within 28 days prior to the first dose. * Participants who have received radiotherapy within 21 days prior to the first dose. * Participants who have received systemic glucocorticoid therapy (more than 10 mg of prednisone or equivalent daily) or other forms of immunosuppressive therapy within 7 days prior to the first dose. * Participants with symptomatic central nervous system metastases. * History of any-grade interstitial lung disease (ILD) or known/suspected ILD. * History of other malignancies within 5 years prior to the first dose, excluding cured basal or squamous cell carcinoma of skin, carcinoma cervix in situ, or breast ductal carcinoma in situ. * Hypersensitivity to the investigational drug or its excipients. * Pregnant or lactating female patients.